Abiopharma

🔍 Mohan Jitendra (Director)

Company: Astera Labs, Inc. (ALAB)

Report Date: 2026-05-07

Detailed Transactions and Holdings:

• Sold 79,377 shares of Common Stock at $199.3269 per share (Direct)
  Date: 2026-05-07 | Code: S | equity_swap_involved: 0 | shares_owned_after: 3,989,757.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Sold 34,234 shares of Common Stock at $200.5254 per share (Direct)
  Date: 2026-05-07 | Code: S | equity_swap_involved: 0 | shares_owned_after: 3,955,523.00 | transaction_form_type: 4 | Footnotes: F1, F4, F3
• Sold 14,875 shares of Common Stock at $201.3982 per share (Direct)
  Date: 2026-05-07 | Code: S | equity_swap_involved: 0 | shares_owned_after: 3,940,648.00 | transaction_form_type: 4 | Footnotes: F1, F5, F3
• Sold 6,048 shares of Common Stock at $202.5059 per share (Direct)
  Date: 2026-05-07 | Code: S | equity_swap_involved: 0 | shares_owned_after: 3,934,600.00 | transaction_form_type: 4 | Footnotes: F1, F6, F3
• Sold 3,146 shares of Common Stock at $203.4479 per share (Direct)
  Date: 2026-05-07 | Code: S | equity_swap_involved: 0 | shares_owned_after: 3,931,454.00 | transaction_form_type: 4 | Footnotes: F1, F7, F3
• Sold 1,311 shares of Common Stock at $204.7172 per share (Direct)
  Date: 2026-05-07 | Code: S | equity_swap_involved: 0 | shares_owned_after: 3,930,143.00 | transaction_form_type: 4 | Footnotes: F1, F8, F3
• Sold 960 shares of Common Stock at $205.7363 per share (Direct)
  Date: 2026-05-07 | Code: S | equity_swap_involved: 0 | shares_owned_after: 3,929,183.00 | transaction_form_type: 4 | Footnotes: F1, F9, F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-07 | Code: H | nature_of_ownership: By Trust | shares_owned_after: 699,999.00 | Footnotes: F10
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-07 | Code: H | nature_of_ownership: By 2021 Trust 1 | shares_owned_after: 700,000.00 | Footnotes: F11
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-07 | Code: H | nature_of_ownership: By 2021 Trust 2 | shares_owned_after: 700,000.00 | Footnotes: F12
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-07 | Code: H | nature_of_ownership: By 2022 Trust 1 | shares_owned_after: 450,001.00 | Footnotes: F13
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-07 | Code: H | nature_of_ownership: By 2022 Trust 2 | shares_owned_after: 450,001.00 | Footnotes: F14
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-07 | Code: H | shares_owned_after: 1,452,739.00

Footnotes:

• F1: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2025.
• F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $199.0000 to $199.9900, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: These shares are owned directly by a living trust (the "Living Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
• F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $200.0000 to $200.9900, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $201.0000 to $201.9900, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F6: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $202.1000 to $203.0600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F7: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $203.1800 to $204.1200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F8: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $204.3900 to $205.3450, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F9: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $205.3900 to $205.9700, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F10: These shares are owned directly by an estate planning trust (the "Trust"). The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
• F11: These shares are owned directly by an estate planning trust (the "2021 Trust 1"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
• F12: These shares are owned directly by an estate planning trust (the "2021 Trust 2"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
• F13: These shares are owned directly by an estate planning trust (the "2022 Trust 1"). The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
• F14: These shares are owned directly by an estate planning trust (the "2022 Trust 2"). The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.